|

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

RECRUITINGPhase 1Sponsored by The Foundation for Orthopaedics and Regenerative Medicine
Actively Recruiting
PhasePhase 1
SponsorThe Foundation for Orthopaedics and Regenerative Medicine
Started2022-02-01
Est. completion2026-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05147701

Summary

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of NAION (non-arteritic ischemic optic neuropathy)
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur

Conditions7

DiabetesDiabetic RetinopathyEye DiseasesMacular DegenerationOptic AtrophyRetinitis PigmentosaTraumatic Optic Neuropathy

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.